



## **Pliant Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference**

December 21, 2021

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, will present a company update as part of the 40<sup>th</sup> Annual J.P Morgan Healthcare Conference. The virtual presentation will begin on Wednesday, January 12, 2022, at 9:45 a.m. ET /6:45 a.m. PT.

Interested parties can access this presentation from the Investor Relations' Events & Presentation page of Pliant's website at <https://ir.pliantx.com/news-and-events/events-and-presentations> with an replay available for 30 days following the conclusion of the event.

### **About Pliant Therapeutics, Inc.**

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of  $\alpha_v\beta_6$  and  $\alpha_v\beta_1$  integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of  $\alpha_v\beta_1$  for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit [www.pliantx.com](http://www.pliantx.com) and follow us on [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

### **Investor and Media Contact:**

Christopher Keenan  
Vice President, Investor Relations and Corporate Communications  
Pliant Therapeutics, Inc.  
[ir@pliantrx.com](mailto:ir@pliantrx.com)